LAB vs. ADPT, OLK, TXG, CTKB, QTRX, EYPT, PACB, NAUT, HBIO, and SEER
Should you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include Adaptive Biotechnologies (ADPT), Olink Holding AB (publ) (OLK), 10x Genomics (TXG), Cytek Biosciences (CTKB), Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), Pacific Biosciences of California (PACB), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), and Seer (SEER).
Adaptive Biotechnologies (NASDAQ:ADPT) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment, institutional ownership and community ranking.
99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 6.2% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 53.1% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Adaptive Biotechnologies received 88 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 56.52% of users gave Adaptive Biotechnologies an outperform vote.
Adaptive Biotechnologies has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.
In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Standard BioTools. MarketBeat recorded 3 mentions for Adaptive Biotechnologies and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.92 beat Adaptive Biotechnologies' score of 0.53 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.
Adaptive Biotechnologies presently has a consensus target price of $6.80, suggesting a potential upside of 88.37%. Standard BioTools has a consensus target price of $3.58, suggesting a potential upside of 54.45%. Given Standard BioTools' higher probable upside, research analysts plainly believe Adaptive Biotechnologies is more favorable than Standard BioTools.
Standard BioTools has a net margin of -70.98% compared to Standard BioTools' net margin of -123.24%. Standard BioTools' return on equity of -56.58% beat Adaptive Biotechnologies' return on equity.
Standard BioTools has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Summary
Standard BioTools beats Adaptive Biotechnologies on 10 of the 18 factors compared between the two stocks.
Get Standard BioTools News Delivered to You Automatically
Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Standard BioTools Competitors List
Related Companies and Tools
